Key Points A tobacco giant shifting to smoke-free products just raised its dividend by 8.9% as next-generation nicotine wins an ever-increasing slice of revenue. A pharmaceutical company trades at 8 times forward earnings with a 7% yield as it raises revenue guidance and reenters the obesity drug market. Both stocks combine immediate income with turnaround potential, though regulatory and execution risks require carefully sizing your positions. 10 stocks we like better than Philip Morris Internation ...